Investor Presentation

• 13% revenue growth, 11% increase in Gateway revenues, 82% gross margin in FY25
• Positive EBITDA of $1.61m, strong cash position of $4.2m
• Marketplace revenues increased 193% compared to FY24

Pharmx Technologies Ltd reported a 13% increase in total revenues to $7.53m for FY25, driven by growth across both the Gateway and Marketplace platforms. Gateway revenues increased by 11% compared to FY24, while Marketplace revenues grew by 193%. The company maintained cost discipline, with a 1% improvement in gross margin to 82%. EBITDA was $1.61m, a 13% decrease compared to the prior year, due to increased investment in personnel, rebranding, marketing, and IT infrastructure. The company ended the year with a strong cash position of $4.2m, after investing $1.7m in product development and paying the final settlement related to the Pharmx legal case. Pharmx continued to expand its network, securing new partnerships and enhancing its platforms, including the rollout of Supplier and Pharmacy Portals, e-commerce enhancements, and infrastructure upgrades. The company also implemented operational efficiency measures, such as the early termination of the Alchemy revenue share agreement and the implementation of new AI tools, CRM, and sales enablement systems. Looking ahead, Pharmx is focused on building a resilient, product-centric Single Platform, embedding operational excellence, and accelerating digitization and automation to drive scalable growth and strengthen its position as the industry's leading multi-channel solution.

Pharmx is focused on building a resilient, product-centric Single Platform, embedding operational excellence, and accelerating digitization and automation to drive scalable growth and strengthen its position as the industry's leading multi-channel solution.